Maiden Pharmaceuticals, which was flagged by the World Health Organization(WHO) after the deaths of nearly 70 children in The Gambia.
As per the report, they did not test the quality of the raw materials used to manufacture any of its drugs.
Investigations are currently ongoing in India and The Gambia.
Regulators said they had suspended all manufacturing operations at the New Delhi-based firm after it violated safety norms.
Haryana drug controllers listed 12 points of contraventions that were detected during the inspection of the company’s Sonepat unit.
